Targeting RBM39 Through Indisulam Induced Mis-Splicing of Mrna to Exert Anti-Cancer Effects in T-cell Acute Lymphoblastic Leukemia.
Tongting Ji,Yang,Juanjuan Yu,Hongli Yin,Xinran Chu,Pengju Yang,Ling Xu,Xiaodong Wang,Shaoyan Hu,Yizhen Li,Xiaochen Wu,Wengyuan Liu,Bi Zhou,Wenjuan Wang,Shuqi Zhang,Wei Cheng,Yanling Chen,Lei Shi,Zhiheng Li,Ran Zhuo,Yongping Zhang,Yanfang Tao,Di Wu,Xiaolu Li,Zimu Zhang,Jun-jie Fan,Jian Pan,Jun Lu
DOI: https://doi.org/10.1186/s13046-024-03130-8
IF: 12.658
2024-01-01
Journal of Experimental & Clinical Cancer Research
Abstract:Despite the use of targeted therapeutic approaches, T-cell acute lymphoblastic leukemia (T-ALL) is still associated with a high incidence of complications and a poor prognosis. Indisulam (also known as E7070), a newly identified molecular glue compound, has demonstrated increased therapeutic efficacy in several types of cancer through the rapid degradation of RBM39. This study aimed to evaluate the therapeutic potential of indisulam in T-ALL, elucidate its underlying mechanisms and explore the role of the RBM39 gene. We verified the anticancer effects of indisulam in both in vivo and in vitro models. Additionally, the construction of RBM39-knockdown cell lines using shRNA confirmed that the malignant phenotype of T-ALL cells was dependent on RBM39. Through RNA sequencing, we identified indisulam-induced splicing anomalies, and proteomic analysis helped pinpoint protein changes caused by the drug. Comprehensive cross-analysis of these findings facilitated the identification of downstream effectors and subsequent validation of their functional roles. Indisulam has significant antineoplastic effects on T-ALL. It attenuates cell proliferation, promotes apoptosis and interferes with cell cycle progression in vitro while facilitating tumor remission in T-ALL in vivo models. This investigation provides evidence that the downregulation of RBM39 results in the restricted proliferation of T-ALL cells both in vitro and in vivo, suggesting that RBM39 is a potential target for T-ALL treatment. Indisulam’s efficacy is attributed to its ability to induce RBM39 degradation, causing widespread aberrant splicing and abnormal translation of the critical downstream effector protein, THOC1, ultimately leading to protein depletion. Moreover, the presence of DCAF15 is regarded as critical for the effectiveness of indisulam, and its absence negates the ability of indisulam to induce the desired functional alterations. Our study revealed that indisulam, which targets RBM39 to induce tumor cell apoptosis, is an effective drug for treating T-ALL. Targeting RBM39 through indisulam leads to mis-splicing of pre-mRNAs, resulting in the loss of key effectors such as THOC1.